Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.59% | 19.41% | 17.19% | 16.11% | 7.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.27% | 2.16% | 10.96% | 24.51% | 9.53% |
| Operating Income | -28.27% | -2.16% | -10.96% | -24.51% | -9.53% |
| Income Before Tax | -5.12% | 12.02% | 0.19% | -15.34% | -23.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.12% | 12.02% | 0.19% | -15.34% | -23.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.12% | 12.02% | 0.19% | -15.34% | -23.04% |
| EBIT | -28.27% | -2.16% | -10.96% | -24.51% | -9.53% |
| EBITDA | -28.26% | -2.13% | -10.93% | -24.50% | -9.51% |
| EPS Basic | -5.77% | 10.83% | -2.02% | -16.28% | -3.22% |
| Normalized Basic EPS | -12.57% | 5.73% | -8.88% | -25.10% | 3.00% |
| EPS Diluted | -5.69% | 10.76% | -2.11% | -16.38% | -3.31% |
| Normalized Diluted EPS | -12.57% | 5.73% | -8.88% | -25.10% | 3.00% |
| Average Basic Shares Outstanding | -0.65% | -1.47% | -2.31% | -0.47% | 13.06% |
| Average Diluted Shares Outstanding | -0.65% | -1.47% | -2.31% | -0.47% | 13.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |